Stereotaxis, Inc. specializes in computer-controlled magnetic navigation technology that precisely manipulates flexible catheter tips during cardiac ablation and other endovascular interventions. Despite advancing its product portfolio and regulatory clearances, the company has faced declining revenue and sustained operating losses. Its commercial model balances capital system sales with recurring disposables and service contracts, but lengthy sales cycles and strategic dependencies limit growth visibility. Expansion into neurovascular and peripheral vascular procedures alongside recent acquisitions offer diversification opportunities, while significant risks remain in regulatory approvals, supply chain single sourcing, and market adoption.